Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunostart: Prephase TRR Followed by TRR + Standard Therapy for Untreated DLBCL
NCT05455697Phase 2Active, not recruiting
- Sponsor
- University of Washington
- Start
- Jan 2023
- Primary completion
- Oct 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tafasitamab, retifanlimab in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), high grade B-cell lymphoma (HGBCL), sponsored by University of Washington. Started Jan 2023; status: active, not recruiting.
02
Drugs
tafasitamabretifanlimab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)high grade B-cell lymphoma (HGBCL)
Beyond the preview
Go deeper on NCT05455697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05455697.